Results 11 to 20 of about 169,886 (331)

Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA [PDF]

Endocrine Connections, 2023
Background: Updated epidemiological data of neuroendocrine tumors are currently lacking. Thus, we performed epidemiological and survival analyses on a large cohort of patients with neuroendocrine tumors and developed a new nomogram to predict survival.
Peiwen Wu, Dongjie He, Hao Chang, Xiaozhi Zhang   +3 more
doaj   +2 more sources

Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors [PDF]

Cell Death and Disease
Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumors (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells, which has not been fully elucidated.
Xin Lou, Yihua Shi, Yi Qin, Wuhu Zhang, Zeng Ye, Fei Wang, Yan Wang, Tian Ding, Desheng Jing, Guixiong Fan, Yue Zhang, Xuemin Chen, Xiaowu Xu, Xianjun Yu, Shunrong Ji, Junfeng Xu   +15 more
doaj   +2 more sources

Molecular reprogramming in thymic neuroendocrine tumors: a narrative review. [PDF]

Mediastinum
Di J, Zhou Y, Hu J.
europepmc   +2 more sources

Gastric Neuroendocrine Tumor [PDF]

The Surgery Journal, 2021
AbstractGastric neuroendocrine tumor (gNET) is a rare carcinoid of the stomach whose incidence is increasing due to widespread use of upper gastrointestinal endoscopy (UGIE). There are four types of gNETs with different management strategies and prognosis. Here, we present a patient who came with abdomen pain and intermittent melena.
Naresh Kargwal, Viraj Panda, Abhijeet Kumar Jha, C. B. Singh   +3 more
openaire   +3 more sources

Neuroendocrine Tumors [PDF]

Journal of the National Comprehensive Cancer Network, 2012
Neuroendocrine tumors comprise a broad family of tumors, the most common of which are carcinoid and pancreatic neuroendocrine tumors. The NCCN Neuroendocrine Tumors Guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine tumors. Most of the recommendations pertain to well-differentiated, low- to intermediate-grade
Matthew H, Kulke, Al B, Benson, Emily, Bergsland, Jordan D, Berlin, Lawrence S, Blaszkowsky, Michael A, Choti, Orlo H, Clark, Gerard M, Doherty, James, Eason, Lyska, Emerson, Paul F, Engstrom, Whitney S, Goldner, Martin J, Heslin, Fouad, Kandeel, Pamela L, Kunz, Boris W, Kuvshinoff, Jeffrey F, Moley, Venu G, Pillarisetty, Leonard, Saltz, David E, Schteingart, Manisha H, Shah, Stephen, Shibata, Jonathan R, Strosberg, Jean-Nicolas, Vauthey, Rebekah, White, James C, Yao, Deborah A, Freedman-Cass, Mary A, Dwyer   +27 more
openaire   +4 more sources

Does epidural analgesia modify the risk of complications after gastrectomy?

Nowotwory, 2021
INTRODUCTION: The surgical treatment of Gastric Cancer is associated with overall complication rates as high as 50%. The intent of this study was to assess the impact of epidural analgesia (EA) on postoperative complication rates among patients ...
Tomasz Olesiński, Marta Urbańska, Anna Borkowska, Paulina Wieszczy, Dariusz Król, Dorota Rucz, Małgorzata Symonides   +6 more
doaj   +1 more source

Evaluation of the incidence of splenic hilar lymph node metastasis in patients operated on for esophagogastric junction cancer

Nowotwory, 2023
INTRODUCTION: The purpose of this study is to evaluate the effect of esophagogastric junction cancer (EGJC) staging on the risk of splenic hilar lymph node involvement. MATERIAL AND METHODS: 312 patients with EGJC after R0 surgery were analyzed; 118 (38%)
Tomasz Olesiński, Marek Szpakowski, Wojciech Każmierczak, Urszula Sulkowska, Andrzej Rutkowski   +4 more
doaj   +1 more source

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues

Biomedicines, 2023
Angiogenic factors (AF) promote vascular formation and may thus support neuroendocrine tumour (NET) development. This study aimed to assess AF serum level changes in NET patients treated with prolonged-acting somatostatin analogues (SSAs).
Violetta Rosiek, Ksenia Janas, Beata Kos-Kudła   +2 more
doaj   +1 more source

Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE)

Biomedicines, 2023
The coronavirus disease-19 (COVID-19) pandemic dramatically impacted oncological patients’ care. Since the introduction of vaccines and the demonstration of their benefit on frail patients, COVID-19 vaccinations were indicated to also be beneficial to ...
Alice Laffi, Lorenzo Gervaso, Oriana D’Ecclesiis, Sara Gandini, Agostino Riva, Rita Passerini, Francesca Spada, Stefania Pellicori, Manila Rubino, Chiara Alessandra Cella, Paola Simona Ravenda, Maria Giulia Zampino, Nicola Fazio   +12 more
doaj   +1 more source

Serum tumor markers for detection of bone metastases in patients with lung neuroendocrine neoplasms”

Cancer Treatment and Research Communications, 2022
Background: Bone metastases (BM) are related to worse outcome in patients with neuroendocrine neoplasms (NENpts). Aim: Assess utility of serum tumor markers (STM) for detection of BM in lung NENpts.
Violetta Rosiek, Monika Wójcik-Giertuga, Beata Kos-Kudła   +2 more
doaj   +1 more source